Beyond approval | Considerations and Challenges in Access to Gene Therapy featuring Nicola Redfern

In this episode of Haemcast, host Dr Kate Khair speaks with Nicola Redfern, former UK General Manager and Northern European cluster lead at bluebird bio and experienced leader in the biopharmaceutical industry, having worked across oncology, rare diseases and ATMPs. We discuss the considerations and challenges when it comes to access of gene therapies, and what the bleeding disorders community can do to ensure these innovative treatments are accepted by payers and become a real option for patients.

Connect with Nicola on LinkedIn

Comments or questions about the show? Connect with us on Twitter and LinkedIn or send us a line to hello@haemnet.com